Krystal Biotech (KRYS) Common Equity (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Common Equity of $1.4 billion for Q2 2026, up 30.6% year-over-year from $1.0 billion in Q2 2025, and up 6.45% on a QoQ basis from $1.3 billion in Q1 2026.
Krystal Biotech (KRYS) Common Equity (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Common Equity for 11 years, with the latest figure at $1.4 billion in Q2 2026.
- Common Equity for Q2 2026 came in at $1.4 billion, up 30.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 30.6% YoY), and the FY2025 annual result was $1.2 billion, up 28.87% from the prior year.
- Common Equity advanced to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
- Over five years, Common Equity peaked at $1.4 billion in Q2 2026 and troughed at $489.6 million in Q1 2023.
- A 5-year average of $852.1 million and a median of $819.1 million in 2024 frame the typical range for Common Equity.
- The widest annual swing landed in 2022, when Common Equity retreated 12.02%; it then soared 63.26% in 2024.
- A 5-year view of Common Equity shows it stood at $522.2 million in 2022, then soared by 49.1% to $778.6 million in 2023, then rose by 21.54% to $946.4 million in 2024, then climbed by 28.87% to $1.2 billion in 2025, then climbed by 11.44% to $1.4 billion in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $1.4 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 1.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Bn |
| Mar 31, 2026 | 1.28 Bn |
| Dec 31, 2025 | 1.22 Bn |
| Sep 30, 2025 | 1.14 Bn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 984.67 Mn |
| Dec 31, 2024 | 946.38 Mn |
| Sep 30, 2024 | 885.85 Mn |
| Jun 30, 2024 | 838.89 Mn |
| Mar 31, 2024 | 799.24 Mn |
| Dec 31, 2023 | 778.64 Mn |
| Sep 30, 2023 | 755.95 Mn |
| Jun 30, 2023 | 653.11 Mn |
| Mar 31, 2023 | 489.57 Mn |
| Dec 31, 2022 | 522.23 Mn |
| Sep 30, 2022 | 540.77 Mn |
| Jun 30, 2022 | 559.18 Mn |
| Mar 31, 2022 | 548.55 Mn |
| Dec 31, 2021 | 593.58 Mn |
| Sep 30, 2021 | 408.24 Mn |